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BACKGROUND
Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no 
conclusive evidence of its benefit. We conducted a multicenter, randomized trial compar-
ing thymectomy plus prednisone with prednisone alone.
METHODS
We compared extended transsternal thymectomy plus alternate-day prednisone with al-
ternate-day prednisone alone. Patients 18 to 65 years of age who had generalized nonthy-
momatous myasthenia gravis with a disease duration of less than 5 years were included 
if they had Myasthenia Gravis Foundation of America clinical class II to IV disease (on a 
scale from I to V, with higher classes indicating more severe disease) and elevated circulat-
ing concentrations of acetylcholine-receptor antibody. The primary outcomes were the 
time-weighted average Quantitative Myasthenia Gravis score (on a scale from 0 to 39, with 
higher scores indicating more severe disease) over a 3-year period, as assessed by means 
of blinded rating, and the time-weighted average required dose of prednisone over a 3-year 
period.
RESULTS
A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. 
Patients who underwent thymectomy had a lower time-weighted average Quantitative 
Myasthenia Gravis score over a 3-year period than those who received prednisone alone 
(6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average re-
quirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the 
thymectomy group than in the prednisone-only group required immunosuppression with 
azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, 
P<0.001). The number of patients with treatment-associated complications did not differ 
significantly between groups (P = 0.73), but patients in the thymectomy group had fewer 
treatment-associated symptoms related to immunosuppressive medications (P<0.001) and 
lower distress levels related to symptoms (P = 0.003).
CONCLUSIONS
Thymectomy improved clinical outcomes over a 3-year period in patients with nonthy-
momatous myasthenia gravis. (Funded by the National Institute of Neurological Disorders 
and Stroke and others; MGTX ClinicalTrials.gov number, NCT00294658.)
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The first reported use of thymec-tomy in patients with nonthymomatous myasthenia gravis was 75 years ago.1 Of 
six patients who underwent surgery, three had a 
favorable response. Subsequent retrospective 
studies have shown benefits of thymectomy in 
patients with nonthymomatous myasthenia gra-
vis but with widely varying rates of clinical im-
provement or remission. A compilation of retro-
spective studies comparing surgery with medical 
management did not show a difference in remis-
sion rates.2 Two studies that showed clinical 
improvements after thymectomy indicated that 
benefit occurred in the first few years after the 
procedure, but after 5 years, rates of clinical 
improvement were similar among surgically 
treated patients and those who were treated 
medically.3,4 Observational studies have not shown 
benefits of thymectomy, perhaps because of the 
effectiveness of modern immunotherapeutic 
approaches.5
Despite calls for a randomized, controlled 
study, data are lacking, and uncertainty persists 
regarding the benefit of thymectomy and the 
clinical characteristics of the patients who 
should be offered the procedure.6,7 A systematic 
review8 of articles describing outcomes in 21 
cohorts of patients with myasthenia gravis 
pointed out numerous methodologic flaws that 
prevented definite conclusions to be drawn re-
garding the benefits of thymectomy in patients 
with nonthymomatous myasthenia gravis.
Glucocorticoids have been widely used for 
the treatment of myasthenia gravis either as the 
sole therapy or with thymectomy.9 Although ad-
verse effects are not common with thymectomy, 
the procedure can cost up to $80,00010 and can 
be associated with operative complications that 
need to be weighed against benefits. Glucocorti-
coids and other immunosuppressive agents place 
patients at risk for adverse events, some of which 
are life-threatening, and affect quality of life. 
Therefore, establishing the role of thymectomy 
in patients receiving glucocorticoids to manage 
myasthenia gravis would guide decisions regard-
ing treatment and the costs of health care.
We conducted the Thymectomy Trial in Non-
Thymomatous Myasthenia Gravis Patients Re-
ceiving Prednisone Therapy (MGTX), an interna-
tional, randomized, single-blind (rater-blinded) 
trial, to determine whether extended transster-
nal thymectomy combined with a standardized 
prednisone protocol would be superior to pred-
nisone alone after 3 years, with respect to less-
ening myasthenic weakness, lowering the total 
dose of prednisone, and enhancing quality of 
life. Extended transsternal thymectomy was cho-
sen because it provides reproducible resection of 
the maximal amount of thymic tissue with low 
morbidity and a limited risk of phrenic-nerve 
injury.11
Me thods
Trial Oversight
The trial was designed and overseen by an ex-
ecutive committee that included lead investiga-
tors and biostatisticians (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). During the proposal and trial-
design phase, feedback was received from re-
viewers and staff at the National Institute of 
Neurological Disorders and Stroke (NINDS). 
There was no commercial support for this trial. 
The NINDS funded the trial and assembled a 
data and safety monitoring board to monitor the 
trial activities independently.
Each trial site received approval from a local 
institutional review board or ethics committee, 
and each patient provided written informed con-
sent before enrollment. Data were collected by 
investigative teams at each trial site. Data analy-
sis and regulatory enforcement were performed 
by staff at the Data Coordinating Center, De-
partment of Biostatistics, University of Alabama 
at Birmingham. Data were managed at the Uni-
versity of Alabama at Birmingham with the use 
of a Web-based system. Notification of serious 
adverse events and visit tracking were performed 
electronically. The first author wrote the first 
draft of the manuscript, with assistance from 
the executive committee. All the authors vouch 
for the accuracy of the data and analyses report-
ed. The trial was conducted and reported with 
fidelity to the protocol, available at NEJM.org.
Trial Design
MGTX was a multicenter, international, rater-
blinded, randomized trial.12 Training meetings 
for investigators were held in 2006 in the United 
States and the United Kingdom, and all the in-
vestigators were required to pass a certification 
test to ensure the best possible adherence to the 
protocol. Thoracic surgeons were certified after 
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viewing a video of the surgical approach and 
passing a test to show that they understood the 
required procedure for excision. Centers were 
asked to complete a screening questionnaire for 
every patient with myasthenia gravis who was 
encountered at their sites.
The original inclusion criteria were a duration 
of myasthenia gravis of less than 3 years, an age 
of 18 to 60 years, a serum acetylcholine-recep-
tor–antibody level of more than 1.00 nmol per 
liter (elevated levels of 0.50 to 0.99 nmol per liter 
were accepted if the diagnosis was confirmed by 
a positive edrophonium test, abnormal repetitive 
nerve stimulation, or abnormal single-fiber elec-
tromyography), and a Myasthenia Gravis Founda-
tion of America clinical classification11 of II to 
IV (class I indicates weakness only in ocular 
muscles, class II mild generalized disease, class 
III moderate generalized disease, class IV severe 
generalized disease, and class V a crisis requir-
ing intubation). Participants could be taking ap-
propriate anticholinesterase therapy with or with-
out oral glucocorticoids. Exclusion criteria were 
thymoma on computed tomography or magnetic 
resonance imaging of the chest, previous thy-
mectomy, immunotherapy other than prednisone, 
pregnancy or lactation, unwillingness to avoid 
pregnancy, contraindications to glucocorticoids, 
and substantial medical illness that would pre-
clude participation.
In October 2008, which was 2 years after 
enrollment began, the eligibility criterion regard-
ing disease duration was increased from less 
than 3 years to less than 5 years and the age 
ceiling was raised from 60 years to 65 years to 
enhance recruitment. In October 2009, the sam-
ple size was reduced from 200 to 150 partici-
pants to reflect a lower-than-expected recruit-
ment rate and better-than-expected retention of 
participants.
Trial Procedures
Participants were stratified according to trial 
site with the use of a Web-based randomization 
system in which participants were assigned, in a 
1:1 ratio, to undergo thymectomy plus receive 
the standardized prednisone protocol or to re-
ceive the same prednisone protocol alone. The 
receipt of prednisone began immediately, and 
surgery was performed within 30 days after ran-
domization. The randomization date was set as 
month 0 (Fig. S1 in the Supplementary Appen-
dix). To preserve rater blinding, participants 
were seen exclusively until month 4, as they 
recovered from surgery, by a neurologist who 
was aware of the trial-group assignments. At all 
visits, participants wore black, high-collared, 
obscuring pullover shirts to conceal transsternal 
incisions; participants were under strict instruc-
tions not to reveal their assigned trial group to 
the evaluators.
Thymectomy was performed by means of a 
median sternotomy with the goal of an en bloc 
resection of all mediastinal tissue that could 
anatomically contain gross or microscopic thy-
mus (or both).11 Photographs of the specimens 
were transmitted to the data coordinating center 
and analyzed by the surgical coordinator to 
judge the extent of resection and compare it with 
a detailed operative report. Operative details are 
summarized in the Supplementary Appendix. 
Data from patients who crossed over to the 
other group and from patients who had thymo-
ma discovered at surgery were handled accord-
ing to an intention-to-treat model.
Participants who were not already receiving 
prednisone at baseline received an alternate-day 
dose of oral prednisone starting at 10 mg, which 
was increased in 10-mg steps to 100 mg on alter-
nate days or to 1.5 mg per kilogram of body 
weight, whichever was lower. For participants 
who were already taking prednisone, the dose 
could be increased up to 120 mg in those who 
did not reach minimal-manifestation status by 
month 4. Minimal-manifestation status was de-
fined as having “no symptoms or functional 
limitations from myasthenia gravis, but there 
may be some weakness on examination of some 
muscles” (see the Supplementary Appendix).11 
The prednisone dose was maintained until min-
imal-manifestation status was reached and the 
Quantitative Myasthenia Gravis score13 (on a scale 
from 0 to 39, with higher scores on each of 13 
items indicating more severe weakness; a reduc-
tion of 2.3 points correlates with improved 
clinical status) was less than 14 and had also 
fallen at least 1 point below baseline, as deter-
mined by an evaluator who was unaware of the 
trial-group assignment.
The alternate-day prednisone dose was then 
reduced by 10 mg every 2 weeks until a level of 
40 mg was reached, with subsequent slowing of 
the taper to 5 mg every month, as long as the 
minimal-manifestation status was maintained. 
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If minimal-manifestation status was lost, the 
alternate-day prednisone dose was increased by 
10 mg every 2 weeks until the status was re-
stored. Tapering could resume 4 weeks later.
Once prednisone tapering commenced, the 
total dose of pyridostigmine could not exceed 
240 mg per day. Plasmapheresis or intravenous 
immune globulin was permitted at the discre-
tion of the unblinded neurologist in patients 
whose condition was unstable, but it was not 
permitted in order to maintain minimal-mani-
festation status. Patients who did not have 
minimal-manifestation status at 12 months or 
who had an unacceptable level of side effects 
with prednisone could receive azathioprine at a 
dose of 2.5 mg per kilogram per day or another 
immunosuppressant such as cyclosporine if 
azathioprine caused unacceptable side effects.
Trial Outcomes
The dual primary outcome was the time-weighted 
average Quantitative Myasthenia Gravis score 
and the time-weighted average required dose of 
prednisone over a 3-year period; this dual out-
come involved a staged approach to incorporat-
ing the potential effect of thymectomy on the 
clinical response to therapy and its influence on 
long-term requirements for glucocorticoid use. 
The rationale for the dual outcome was that an 
improved clinical status could correlate with a 
greater prednisone dose and a poorer clinical 
status with a lower dose. The first stage of 
analysis compared the clinical outcomes between 
groups according to the time-weighted average 
Quantitative Myasthenia Gravis score over a pe-
riod of 3 years, which was roughly equivalent to 
the average score over time.14 On the basis of the 
results of the between-group comparison of the 
clinical outcomes (clinical improvement, worsen-
ing, or status unchanged), we analyzed the dif-
ference in the total required dose of prednisone 
over the period of 3 years (see below).
Prednisone was administered in blister packs 
containing 10-mg tablets, with separate sheets 
provided for each dose. Alternate-day dosing 
between visits was recorded by the patient in a 
diary. At each clinic visit, pill counts were de-
rived from returned blister packs to determine 
intake and were compared with the diaries. Pill 
cutters were provided for 5-mg dosing, and un-
used half pills were returned to the blister-pack 
sheets. Pill counts formed the basis for deter-
mining the cumulative prednisone exposure, but 
for confirmation purposes, a secondary analysis 
that used the prescribed dose was performed, 
which was independent of adherence by the pa-
tients.
To address safety and quality of life, second-
ary analyses focused on serious adverse events, 
including days of hospitalization over the 3-year 
period, on the results of surveys of the patients 
that were adapted from the cardiac-transplanta-
tion literature15 to assess 36 treatment-associated 
complications and 29 symptoms associated with 
glucocorticoids (see the Supplementary Appen-
dix), and on results of the Medical Outcomes 
Study 36-Item Short Form Health Survey (SF-36). 
An order of importance of secondary-outcome 
measures was not prespecified. Measures per-
taining to quality of life were to be used for 
further analysis if the tiered primary outcome 
was inconclusive, such as if the time-weighted 
Quantitative Myasthenia Gravis score favored the 
thymectomy group but at the cost of a higher 
prednisone exposure. Other secondary outcomes 
were the Myasthenia Gravis Activities of Daily 
Living score (on a scale from 0 to 24, with 
higher scores indicating more severe disease; 
a reduction of 2 points correlates with improved 
clinical status),16,17 the proportion of participants 
who achieved minimal-manifestation status, and 
the use of nonglucocorticoid immunosuppres-
sants, plasma exchange, and intravenous immune 
globulin.
Laboratory monitoring included a complete 
blood count and glucose, glycated hemoglobin, 
and potassium levels measured at least month-
ly from month 0 to month 3 and then every 
3 months thereafter. Laboratory monitoring that 
was performed in patients who were treated 
with azathioprine or cyclosporine is described in 
the Supplementary Appendix.
Statistical Analysis
The trial was powered to detect a 30% difference 
in the time-weighted prednisone dose between 
the groups, which resulted in a proposed sample 
size of 150 participants on the basis of Student’s 
t-test for two independent samples, at a 5% sig-
nificance level, assuming a mean-to-standard-
deviation ratio of 2.0. The denominator that was 
used to compute the time-weighted average for 
the Quantitative Myasthenia Gravis score and 
the prednisone dose was the number of days 
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from randomization to the last visit. Computa-
tions used the trapezoidal method. The inten-
tion-to-treat method was used for all outcome 
analyses.
For the first stage of the primary analysis, the 
protocol specified that first a 99.5% confidence 
interval for the difference (prednisone-only group 
minus the thymectomy group) in the time-
weighted average Quantitative Myasthenia Gra-
vis score would be assessed. If the confidence 
interval contained zero, the clinical outcome 
would be considered as not being better in one 
group than the other. The second stage would 
determine superiority on the basis of the expo-
sure to prednisone with the use of a two-sided 
Student’s t-test of the time-weighted average 
prednisone dose, at a type I error rate of 0.05, 
given the clinical outcome. Three imputation 
methods were used for missing data (see the 
Supplementary Appendix).
The protocol prespecified the analysis of 
three subgroups (defined according to previous 
or no previous glucocorticoid use, sex, and age 
at disease onset of <40 years vs. ≥40 years). We 
conducted a post hoc analysis of subgroups de-
fined according to an age at enrollment of less 
than 50 years versus 50 years or older. Details of 
the analysis are provided in the Supplementary 
Appendix. There were no planned adjustments 
for multiple secondary outcomes.
At the outset of the trial, investigators were 
asked to predict whether the trial would show a 
favorable effect for thymectomy (Table S1 in the 
Supplementary Appendix). These responses re-
mained sealed until the closure of the trial.
R esult s
Participants
Details regarding recruitment of the participants 
are provided in Figure S1 in the Supplementary 
Appendix. A total of 67 centers in 18 countries 
on six continents (North America, South Amer-
ica, Europe, Africa, Asia, and Australia) partici-
pated, with 36 centers conducting recruitment; 
32 participating centers were in the United States. 
A total of 6958 persons underwent screening, 
3003 of whom were in the United States. A total 
of 6727 patients did not meet the inclusion 
criteria. The main reasons for exclusion were 
duration of disease of 5 years or more (3129 
participants [47%]), an age that did not meet 
specifications (2842 [42%]), use of nonglucocor-
ticoid immunosuppressive drugs (1977 [29%]), 
and previous thymectomy or chest surgery (1901 
[28%]); multiple reasons for exclusion could 
have applied to individual patients. Of the 231 
eligible patients, 105 declined to participate, and 
126 underwent randomization between Septem-
ber 2006 and November 2012 (Fig. S1 in the 
Supplementary Appendix). There were no sig-
nificant between-group differences in the char-
acteristics at baseline (Table 1).
Eight patients who were randomly assigned 
to the thymectomy group declined surgery. Eight 
patients who were randomly assigned to the 
prednisone-only group underwent thymectomy 
outside the protocol (Fig. S1 in the Supplemen-
tary Appendix). Histologic findings are reported 
in Table S2 in the Supplementary Appendix. One 
thymoma was discovered in a patient in the thy-
mectomy group.
Analysis of Two-Stage Primary Outcome
In the first stage of the analysis, the time-
weighted average Quantitative Myasthenia Gravis 
scores were significantly lower (indicating im-
proved clinical status) in the thymectomy group 
than in the prednisone-only group through 
month 36 (P<0.001) (Fig. 1A and Table 2). The 
estimated difference in the mean score between 
the thymectomy group and the prednisone-only 
group was 2.85 points (99.5% confidence inter-
val [CI], 0.47 to 5.22).
Analyses in the second stage showed that 
over a period of 36 months, the time-weighted 
average prednisone dose was significantly lower 
in the thymectomy group than in the prednisone-
only group (Fig. 1B and Table 2). The average 
alternate-day dose was 44 mg in the thymectomy 
group, as compared with 60 mg in the predni-
sone-only group (estimated difference, 16 mg; 
95% CI, 7 to 25; P<0.001). Less than 1% of the 
trial visits in the prednisone-only group were 
missed, as compared with 1% of those in the 
thymectomy group. None of the imputation 
methods for the missing data changed the un-
derlying findings.
Subgroup Analysis
The tests for interactions were not significant in 
any of the three subgroup analyses, and there-
fore, conclusions cannot be drawn about differ-
ential benefits in the subgroups. A total of 26 
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participants had not previously used glucocorti-
coids. Use of the drug was not clear in 4 patients, 
3 of whom were in the prednisone-only group. 
Among participants who had not taken gluco-
corticoids previously, the between-group differ-
ences in the Quantitative Myasthenia Gravis 
score and the prednisone dose were not signifi-
cant; among patients with previous exposure to 
glucocorticoids, the between-group differences 
were significant (Table 2). Among women, the 
between-group differences in the two outcomes 
were significant; among men, the difference in 
prednisone dose was significant. Thymectomy 
was associated with a significantly lower time-
weighted average Quantitative Myasthenia Gravis 
score (indicating clinical improvement) than pred-
nisone alone both in participants with disease 
onset at less than 40 years of age and in those 
with disease onset at 40 years of age or older 
(Table 2).
Secondary Outcome Measures
The survey regarding treatment-associated com-
plications showed no significant difference be-
tween the two treatment groups over a period 
of 3 years (P = 0.73). The survey regarding treat-
ment-associated symptoms favored the thymec-
tomy group over the prednisone-alone group in 
the number of participants with symptoms 
(P<0.001), in the total number of symptoms 
(P<0.001), and in the distress level related to 
symptoms (P = 0.003) over the 3-year period. No 
significant between-group differences were seen 
in either the physical or the mental component 
of the SF-36. Details regarding these outcomes 
are provided in Tables S5, S6, and S7 in the 
Supplementary Appendix.
Table 3 lists data regarding adverse events. 
Fewer patients were hospitalized for exacerba-
tions of myasthenia gravis in the thymectomy 
group than in the prednisone-only group (9% vs. 
37%, P<0.001). The mean (±SD) cumulative 
number of hospital days was 8.4±8.6 in the 
thymectomy group, as compared with 19.2±24.5 
in the prednisone-only group (P = 0.09).
When we compared prednisone requirements 
on the basis of prescribed dose instead of pill 
counts, the pattern favoring thymectomy over 
prednisone alone persisted (43 mg vs. 59 mg, 
P = 0.001) (see the Supplementary Appendix). 
Similarly, other findings favored thymectomy 
over prednisone alone, including the time-
weighted average score on the Myasthenia Gravis 
Activities of Daily Living scale (2.24 vs. 3.41, 
P = 0.008), azathioprine use (17% vs. 48% of 
participants, P<0.001), and the percentage of 
Characteristic
Prednisone 
Alone 
(N = 60)
Thymectomy 
plus Prednisone 
(N = 66)
Female sex — no. (%) 39 (65) 50 (76)
Age — yr
Median 33 32
Range 18–64 18–63
Race or ethnic group — no. (%)†
Asian 4 (7) 6 (9)
Black 6 (10) 7 (11)
Hispanic 17 (28) 17 (26)
Non­Hispanic white 30 (50) 31 (47)
Other 3 (5) 5 (8)
Therapy at enrollment — no. (%)
Pyridostigmine 56 (93) 60 (91)
Glucocorticoid 47 (78) 49 (74)
Previous therapy — no. (%)
Intravenous immune globulin 13 (22) 12 (18)
Plasma exchange 7 (12) 9 (14)
MGFA class — no. (%)‡
IIa 25 (42) 25 (38)
IIb 14 (23) 18 (27)
III 20 (33) 21 (32)
IV 1 (2) 2 (3)
Duration of disease — yr
Median 1.14 1.08
Range 0.15–4.38 0.02–4.41
QMG score§ 12.35±4.90 11.40±5.12
Prednisone use at baseline
No. of patients (%) 47 (78) 49 (74)
Dose — mg 42.49±23.52 43.43±28.92
*  Plus–minus values are means ±SD. There were no significant between­group 
differences in the characteristics at baseline. Percentages may not sum to 100 
because of rounding.
†  Race and ethnic group were self­reported. Other race included mixed race, 
Native American, and Alaskan Native.
‡  Myasthenia Gravis Foundation of America (MGFA) class II indicates mild 
generalized weakness, class III moderate generalized weakness, and class IV 
severe generalized weakness. A notation of “a” denotes predominantly limb 
or axial weakness, and “b” predominantly bulbar weakness.
§  Three participants in the group that received prednisone alone and one in the 
thymectomy group withdrew without completing the baseline Quantitative 
Myasthenia Gravis (QMG) test. QMG scores range from 0 to 39, with higher 
scores indicating more severe disease.
Table 1. Demographic and Clinical Characteristics of the Participants  
at Baseline.*
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patients who had minimal-manifestation status 
at month 36 (67% vs. 47%, P = 0.03) (Table S4 in 
the Supplementary Appendix). In an analysis 
that maintained the prednisone dose at the time 
that azathioprine was added through month 36, 
we found that prednisone exposure was 33% 
lower in the thymectomy group than in the 
prednisone-only group (average alternate-day re-
quirement, 46 mg vs. 68 mg; difference, 22 mg; 
95% CI, 11 to 34; P<0.001). Other secondary 
outcomes (use of plasma exchange, use of intra-
venous immune globulin, Myasthenia Gravis 
Activities of Daily Living score, minimal-mani-
festation status, and hospitalizations at time 
points before 3 years) are summarized in the 
Supplementary Appendix.
Unblinding
Over the 9-year period of trial visits, six episodes 
of self-reported unblinding of the rater occurred. 
One participant became pregnant, and trial per-
sonnel were informed of the treatment-group 
assignment for safety reasons. In the other cases, 
two episodes of unblinding occurred when pa-
tients crossed over to the thymectomy group 
and three when unblinded personnel performed 
assessments because the blinded evaluator was 
unavailable.
Discussion
This trial provides evidence supporting the use 
of thymectomy for improving clinical outcomes 
and reducing the need for immunosuppressive 
therapy in patients with myasthenia gravis. Over 
a period of 3 years, thymectomy was associated 
with a more favorable outcome than was predni-
sone alone, with a difference in Quantitative 
Myasthenia Gravis scores that correlated with 
clinically significant improvement.13,14 In this 
trial, thymectomy was associated with a score 
that was 2.85 points lower than that with medi-
cal therapy alone. The minimal clinically impor-
tant difference for this scale has not been deter-
mined, but in a study assessing the validity of 
this scale, scores were 2.3 points lower in pa-
tients who were assessed by neurologists as hav-
ing had clinical improvement over time.14 The 
time-weighted average required alternate-day 
prednisone dose was significantly lower in the 
thymectomy group than in the prednisone-only 
group.
The finding that prednisone doses at month 
36 were higher in each group than might be 
predicted (according to routine practice) could 
be related to the protocol requirement to main-
tain minimal manifestation of disease and lower 
use of glucocorticoid-sparing agents. Patients in 
the prednisone-only group were more likely than 
those in the thymectomy group to be treated 
with azathioprine. We do not believe that even 
greater use of glucocorticoid-sparing immuno-
suppressive drugs in the prednisone-only group 
would have negated the improved clinical out-
comes that were associated with thymectomy. 
Randomized trials of mycophenolate mofetil did 
not show improved clinical outcomes when the 
drug was added to prednisone in patients with 
myasthenia gravis.18,19 The inability of this trial 
Figure 1. Quantitative Myasthenia Gravis Score and Prednisone Dose, 
 According to Treatment Group.
Quantitative Myasthenia Gravis scores range from 0 to 39, with higher 
scores on each of 13 items indicating more severe disease; a reduction of  
2.3 points correlates with improved clinical status. I bars indicate standard 
errors.
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to show significant between-group differences 
among men with respect to the Quantitative 
Myasthenia Gravis score or in the subgroup of 
patients who had not taken prednisone previ-
ously with respect to either of the coprimary 
outcomes may relate to the small number of 
patients but is worth further exploration.
Thymectomy for the treatment of myasthenia 
gravis is based on several lines of evidence that 
support a central role of the thymus in the 
pathogenesis of the disease.20,21 Thymomas are 
present in 10% of patients with myasthenia gra-
vis, and thymectomy is considered to be manda-
tory to prevent further spread.21 Up to 70% of 
the remaining patients with myasthenia gravis 
have hyperplastic thymic changes that are not 
seen in healthy persons.20,22 However, the suc-
cess of immunotherapy has raised questions re-
garding whether such an operation is necessary.2 
A U.S. database suggests that hospital admissions 
Outcome Prednisone Alone
Thymectomy 
plus Prednisone
Estimated Difference 
(95% CI)† P Value‡
value
no. of 
patients value
no. of 
patients
Primary analyses
Time­weighted average QMG score over 3­yr 
period
8.99±4.93 56 6.15±4.09 62 2.85 (0.47 to 5.22) <0.001
Time­weighted average alternate­day predni­
sone dose over 3­yr period (mg)
60±27 56 44±21 61 16 (7 to 25) <0.001
Subgroup analyses
Time­weighted average QMG score
Prednisone use at enrollment 0.86
Yes 9.10±5.06 46 6.30±3.89 47 2.80 (0.11 to 5.49) 0.004
No 8.84±4.60 9 5.66±4.79 15 3.18 (−3.03 to 9.39) 0.12
Sex 0.57
Female 9.73±5.16 38 6.47±4.13 46 3.26 (0.34 to 6.18) 0.002
Male 7.45±4.11 18 5.23±3.95 16 2.22 (−1.96 to 6.40) 0.12
Age at disease onset 0.74
<40 yr 9.60±5.32 34 6.50±4.41 42 3.10 (−0.13 to 6.33) 0.007
≥40 yr 7.85±3.50 18 5.33±2.79 18 2.52 (−0.65 to 5.69) 0.02
Time­weighted average alternate­day predni­
sone dose (mg)
Prednisone use at enrollment 0.37
Yes 61±28 46 44±22 46 17 (7 to 28) 0.002
No 48±19 9 42±20 15 7 (−10 to 24) 0.40
Sex 0.32
Female 59±25 37 46±23 45 13 (3 to 24) 0.01
Male 61±32 19 38±15 16 23 (6 to 40) 0.009
Age at disease onset 0.94
<40 yr 61±27 33 45±22 41 16 (4 to 27) 0.007
≥40 yr 56±28 19 41±21 18 15 (−1 to 32) 0.07
*  CI denotes confidence interval.
†  We used 95% confidence intervals in all analyses except for analyses involving the QMG score, for which we used 99.5% confidence inter­
vals, per protocol.
‡  P values for between­group comparisons are based on two independent sample Student’s t­tests. P values for interaction with treatment 
were based on fitting a general linear model separately for each variable.
Table 2. Primary and Subgroup Analyses of the Primary Outcomes.*
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for thymectomy in patients with myasthenia 
gravis fell dramatically after 2000.23 Planned 
analysis of trial data to assess for correlation 
between histologic findings and response to 
thymectomy have not yet been conducted.
Extended transsternal thymectomy requires 
median sternotomy and is associated with a re-
section of 85 to 95% of thymic tissue.11,24 The 
MGTX did not test less-invasive thymectomy ap-
proaches that have similar effectiveness and 
shorter postoperative recovery times and better 
cosmesis.25-29 One concern is that surgeons who 
use minimally invasive techniques may leave 
behind ectopic thymic tissue in perithymic and 
pericardial fields.24 In some studies, ectopic thy-
mus has had a negative effect on outcomes at a 
follow-up of more than 7 years.30 Furthermore, 
numerous reports describe patients with myas-
thenia gravis as not having clinical improvement 
after incomplete thymic resections.31-33 Random-
ized trials to compare resectional techniques are 
needed.
Potential limitations of our trial include its 
single-blind nature and the pill-count method. It 
Variable
Prednisone 
Alone 
(N = 60)
Thymectomy 
plus Prednisone 
(N = 66) P Value
No. of events 93 48 <0.001†
≥1 event — no. of patients (%) 33 (55) 25 (38) 0.05‡
Event
Life­threatening event — no. of patients (%) 7 (12) 1 (2) 0.03§
Disability or incapacity — no. of patients (%)¶ 2 (3) 8 (12) 0.10
Event requiring medical or surgical intervention  
— no. of patients (%)
5 (8) 9 (14) 0.40
Death — no. of patients (%) 1 (2) 0 0.48
Complication due to thymectomy — no. of patients (%) NA 1 (2) —
Hospitalization — no. of patients (%) 31 (52) 15 (23) <0.001‡
Hospitalization for exacerbation of myasthenia  
gravis — no. of patients (%)
22 (37) 6 (9) <0.001‡
Cumulative no. of hospital days 19.2±24.5 8.4±8.6 0.09
Reason for hospitalization according to MedDRA term  
— no. (%)
Gastrointestinal disorder 2 (3) 2 (3) 1.00
Hepatobiliary disorder 1 (2) 0 0.48
Infection or infestation 7 (12) 4 (6) 0.35
Injury, poisoning, or procedure complication 0 2 (3) 0.50
Metabolism or nutrition disorder 0 1 (2) 1.00
Nervous system disorder 22 (37) 8 (12) 0.001‡
Respiratory, thoracic, or mediastinal disorder 2 (3) 1 (2) 0.60
Surgical or medical procedure 7 (12) 0 0.005§
Vascular disorder 1 (2) 0 0.48
*  Plus–minus values are means ±SD. MedDRA denotes Medical Dictionary for Regulatory Activities, and NA not applicable.
†  The P value is based on Poisson regression that included all 126 patients.
‡  The P value is based on a chi­square test that included all 126 patients.
§  The P value is based on Fisher’s exact test that included all 126 patients.
¶  Causes of disability or incapacity in the group that received prednisone alone included worsening swallowing difficulties 
and myasthenia gravis; causes in the thymectomy group included osteoporotic thoracic fracture, ocular­muscle involve­
ment due to relapsing myasthenia gravis, post­thymectomy diaphragmatic hemiparesis, rib fracture, impending myas­
thenic crisis, ankle fracture, tear of left knee meniscus, and low back pain with possible stenosis.
Table 3. Adverse Events.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on October 13, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;6 nejm.org August 11, 2016520
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
was deemed unethical to subject control patients 
to a transsternal sham thymectomy. A clinical 
measure alone could not be used as the primary 
end point since it would not account for the 
prednisone use that would be required to achieve 
minimal-manifestation status, which can occur 
with glucocorticoids alone.9 We used pill counts 
to measure prednisone intake, but pill counts are 
not a precise measure of actual intake (for com-
parison with other methods, see the Supplemen-
tary Appendix).
In conclusion, this randomized, medication-
controlled, rater-blinded trial showed a benefit 
of thymectomy in patients with myasthenia gra-
vis over a period of 3 years with respect to clini-
cal outcomes, requirements for prednisone and 
azathioprine therapy, the number of symptoms 
and the distress level related to immunosuppres-
sive agents, and the need for hospitalization to 
manage disease exacerbations.
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